Marshall Fordyce Sells 17,500 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 17,500 shares of the stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $43.07, for a total value of $753,725.00. Following the completion of the sale, the chief executive officer now owns 85,942 shares in the company, valued at approximately $3,701,521.94. This trade represents a 16.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, December 11th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $46.94, for a total transaction of $821,450.00.
• On Wednesday, October 23rd, Marshall Fordyce sold 19,375 shares of Vera Therapeutics stock. The shares were sold at an average price of $40.39, for a total transaction of $782,556.25.
• On Wednesday, October 9th, Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock. The shares were sold at an average price of $38.24, for a total transaction of $597,500.00.
• On Wednesday, September 25th, Marshall Fordyce sold 23,125 shares of Vera Therapeutics stock. The stock was sold at an average price of $46.05, for a total transaction of $1,064,906.25.

Vera Therapeutics Price Performance

VERA stock opened at $42.60 on Monday. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The firm has a market cap of $2.70 billion, a price-to-earnings ratio of -16.32 and a beta of 1.08. The company’s fifty day simple moving average is $45.27 and its 200 day simple moving average is $40.50. Vera Therapeutics, Inc. has a 12-month low of $14.20 and a 12-month high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). On average, analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Institutional Trading of Vera Therapeutics

Large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. boosted its stake in Vera Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after acquiring an additional 350 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Vera Therapeutics by 14.4% during the second quarter. Arizona State Retirement System now owns 9,907 shares of the company’s stock valued at $358,000 after purchasing an additional 1,250 shares during the period. Ensign Peak Advisors Inc boosted its position in shares of Vera Therapeutics by 13.5% during the 2nd quarter. Ensign Peak Advisors Inc now owns 11,750 shares of the company’s stock worth $425,000 after purchasing an additional 1,400 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Vera Therapeutics by 30.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,527 shares of the company’s stock valued at $272,000 after buying an additional 1,737 shares during the period. Finally, Handelsbanken Fonder AB increased its position in Vera Therapeutics by 19.0% in the 3rd quarter. Handelsbanken Fonder AB now owns 13,800 shares of the company’s stock valued at $610,000 after buying an additional 2,200 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $107.00 target price on shares of Vera Therapeutics in a research note on Tuesday, October 1st. Evercore ISI upgraded Vera Therapeutics to a “strong-buy” rating in a research report on Monday, September 16th. Scotiabank began coverage on shares of Vera Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $60.00 target price for the company. Wells Fargo & Company assumed coverage on shares of Vera Therapeutics in a research report on Thursday, November 21st. They set an “overweight” rating and a $70.00 price target on the stock. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $59.22.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.